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Abstract: Drug-resistant Pseudomonas aeruginosa is rapidly developing resulting in a serious global
threat. Immunocompromised patients are specifically at risk, especially those with cystic fibrosis
(CF). Novel metal complexes incorporating 1,10-phenanthroline (phen) ligands have previously
demonstrated antibacterial and anti-biofilm effects against resistant P. aeruginosa from CF patients
in vitro. Herein, we present the in vivo efficacy of {[Cu(3,6,9-tdda)(phen)2 ]·3 H2 O·EtOH}n (Cu-tddaphen), {[Mn(3,6,9-tdda)(phen)2 ]·3 H2 O·EtOH}n (Mn-tdda-phen) and [Ag2 (3,6,9-tdda)(phen)4 ]·EtOH
(Ag-tdda-phen) (tddaH2 = 3,6,9-trioxaundecanedioic acid). Individual treatments of these metal-tddaphen complexes and in combination with the established antibiotic gentamicin were evaluated in vivo
in larvae of Galleria mellonella infected with clinical isolates and laboratory strains of P. aeruginosa.
G. mellonella were able to tolerate all test complexes up to 10 µg/larva. In addition, the immune
response was affected by stimulation of immune cells (hemocytes) and genes that encode for immunerelated peptides, specifically transferrin and inducible metallo-proteinase inhibitor. The amalgamation of
metal-tdda-phen complexes and gentamicin further intensified this response at lower concentrations,
clearing a P. aeruginosa infection that were previously resistant to gentamicin alone. Therefore this
work highlights the anti-pseudomonal capabilities of metal-tdda-phen complexes alone and combined
with gentamicin in an in vivo model.
Keywords: Pseudomonas aeruginosa; Galleria mellonella; in vivo model; infection; metal complexes;
1,10-phenanthroline; antimicrobial resistance
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1. Introduction

iations.

Antimicrobial resistance (AMR) endangers the effective prevention and treatment of
an expanding scope of infections caused by microorganisms that are no longer susceptible
to the standard therapies used to manage them [1]. This presents a widespread and urgent
threat to global health. Of particular concern are Gram-negative bacteria with surging
resistance profiles especially to the last line of antibiotics [2]. The Gram-negative human
pathogen, Pseudomonas aeruginosa, is a noteworthy contributor to elevated AMR prevalence
and is frequently isolated from a diverse range of acute, chronic, and biofilm-associated
infections. Most strains now present as multidrug-resistant which increase morbidity
in infected patients, particularly those with cystic fibrosis (CF) [3–5]. The World Health
Organization (WHO) deemed P. aeruginosa a critical priority pathogen urgently requiring
the investigation of new agents to tackle its infections [6]. However, approximately 75% of
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the therapeutics under clinical assessment are derived from already established antimicrobials, of which multiple resistance mechanisms have been reported [7]. This highlights the
clear necessity to investigate novel drugs with unique modes of action that can overcome
these resistant pathways. Consequently, research into many non-antibiotic therapeutic
approaches have been investigated including phage therapy [8], immunotherapy [9], and
antimicrobial peptides [10–12]. In addition, inorganic complexes with 1,10-phenanthroline
(phen) ligands have had a resurgence as possible alternatives or additives to established
antimicrobial therapeutics [13–15]. Transition metal complexes containing phen or its
derivatives have demonstrated promising therapeutic capabilities against bacteria [16,17],
fungi [18–20], parasites [21–23], and viruses [24–26].
We recently demonstrated the activity profiles of manganese(II), copper(II), and silver(I) complexes incorporating 1,10-phenanthroline (phen) and 3,6,9-trioxaundecanedioate
(tddaH2 ) against P. aeruginosa strains isolated from the lungs of CF patients [27]. These
metal-tdda-phen complexes and the antibiotic gentamicin were assessed alone and combined on the planktonic growth, biofilm formation, and mature biofilm formation of the
clinical isolates. The results showed the metal-tdda-phen complexes could prevent biofilm
formation, with relation to mass and cellular viability, to a greater capacity than gentamicin
across the clinical strains, and disturb mature biofilm. Gentamicin, in combination with
the metal-tdda-phen complexes, displayed synergistic activity against the establishment of
mature biofilms. This was supported by reducing the separate biofilm components examined, suggesting extracellular DNA (eDNA) and extracellular polysaccharides as potential
molecular targets. The same complexes also previously demonstrated antitubercular [28]
and antifungal [29] capabilities. The inclusion of the phen is paramount to their potency,
with the addition of tddaH2 enhancing their water solubility and mode of action in various
microbial cells. The ability to act on P. aeruginosa clinical isolates synergistically with gentamicin on mature biofilms prompted the in vivo studies, using larvae of the greater wax
moth Galleria mellonella, reported within.
G. mellonella larvae are a valuable model system for assessing in vivo toxicity and
mechanism of action studies of novel drugs. Low cost, ease of handling, and maintenance
are desirable factors for using the larval model. They have a relatively short life cycle
(40–60 days), and can survive at 37 ◦ C which is an important attribute when assessing
virulence and treatment of human pathogens [30]. Therefore, G. mellonella has been extensively utilized to evaluate the pathogenicity of bacterial and fungal pathogens [31–33],
study biofilm formation [34], measure the in vivo toxicity of novel compounds [35,36],
and determine the in vivo efficacy of established [37,38] and novel [19,39] antimicrobial
agents. Moreover, studies assessing G. mellonella and mammalian models have reported a
correlation in results obtained. Jander et al. [40] demonstrated similar virulence patterns
in larvae and mice injected with P. aeruginosa mutants, and Brennan et al. [41] identified
corresponding virulence patterns between Candida albicans in the aforementioned models.
The generation of comparable data is due to the high degree of structural and functional
analogies across human innate immunity and the insect immune response, composed of
physical barriers and interconnected cellular and humoral responses [42,43]. Although the
larvae do not have an adaptive immune system, they possess sophisticated systems for
non-self-recognition and defence reactions. The hemolymph of G. mellonella consists of
several hemocyte types, of which plasmatocytes and granular cells are the most common.
These cells are similar to human neutrophils and macrophages, being involved in phagocytosis and encapsulation, resulting in an oxidation burst [44]. The humoral response consists
of effector molecules such as antimicrobial peptides (AMPs), opsonins, and lytic enzymes
that appear in the hemolymph to remove pathogens. In particular, AMPs have been found
to destabilize membranes of invading microorganisms [45] as a mode of action. The humoral system also includes activating the phenoloxidase pathway, resulting in melanization
species hydrogen peroxide and superoxide during the pathogen encapsulation [46].
Herein, we assess the pathogenicity of laboratory strains and clinical isolates of
P. aeruginosa using this in vivo model of G. mellonella and the further therapeutic potential
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of manganese(II), copper(II), and silver(I) complexes incorporating 1,10-phenanthroline
(phen) and 3,6,9-trioxaundecanedioate (tddaH2 ) ligands. Pathogenicity was characterized
by the density of hemocytes and bacterial burden in the hemolymph of the larvae at several
time points during infection with the clinical strains of P. aeruginosa. Simultaneously, the
ability of the metal-tdda-phen complexes alone and combined with standard antibiotic
gentamicin to interfere with the larval immune response was demonstrated. The antibacterial activity of the metal-tdda-phen complexes, alone and combined with gentamicin,
against the P. aeruginosa laboratory strains and clinical isolates inoculated in G. mellonella
are also presented.
2. Materials and Methods
2.1. Pseudomonas aeruginosa Strains and Culture Conditions
Pseudomonas aeruginosa (CF1, CF2, and CF3) isolated from cystic fibrosis (CF) patients
at local Irish hospitals, with multidrug-resistant mechanisms [27], and standard laboratory
strains ATCC 27853 and PAO1 were used in this study. Bacterial stocks were maintained
on nutrient agar (Lab M) plates. Before experiments, a single colony was transferred to
nutrient broth (Lab M) and grown at 37 ◦ C and 200 rpm overnight. Bacterial cultures were
adjusted by absorbance (OD600 ), harvested by centrifugation (2000× g), and washed twice
with phosphate-buffered saline (PBS) prior to G. mellonella inoculation [47].
2.2. Galleria mellonella Larvae Monitoring
Larvae of the greater wax moth G. mellonella (Livefoods Direct Ltd., Sheffield, UK)
were stored in wood chippings at 15 ◦ C in darkness to prevent pupation. Larvae weighing
0.25 ± 0.05 g with no cuticle discoloration were selected. Ten healthy larvae per treatment
and controls were used per experimental parameter. All experiments were performed
independently on three separate occasions.
2.3. Test Complexes
The metal complexes used for this study, {[Cu(3,6,9-tdda)(phen)2]·3H2O·EtOH}n (Cu-tddaphen), {[Mn(3,6,9-tdda)(phen)2]·3H2O·EtOH}n (Mn-tdda-phen), and [Ag2(3,6,9-tdda)(phen)4] ·EtOH
(Ag-tdda-phen) were prepared using previously reported methods [29,48]. In addition, the
free ligands, 1,10-phenanthroline (phen) and 3,6,9-trioxaundecanedioic acid (tddaH2 ), were
also assessed. Gentamicin (Sigma-Aldrich, Kent, UK), an aminoglycoside antibiotic used
to treat CF patients infected with P. aeruginosa, was also incorporated. All three clinical
isolates demonstrated resistance to this antibiotic [27].
2.4. Galleria Mellonella Infection Studies with Pseudomonas aeruginosa Strains
2.4.1. Bacterial Infection of G. mellonella
In the pathogenicity studies, ATCC 27853, PAO1, CF1, CF2, and CF3 were investigated
by preparing a dilution series (3 × 100 to 3 × 105 CFU/mL) of each isolate, and ten larvae
were inoculated through the last left pro-leg into the hemocoel using a Myjector U-100
insulin syringe (Terumo Europe NV, Leuven, Belgium) with 20 µL of washed cultures.
Undisturbed larvae and larvae inoculated with PBS were utilized as controls. The injected
larvae were placed in petri dishes containing wood shavings and were incubated at 37 ◦ C.
Mortality, cuticle discoloration, and response to touch were recorded 96 h post-injection.
All experiments were performed independently on three separate occasions.
2.4.2. Determination of Hemocyte Density
Hemocyte density was determined after the inoculation of larvae with laboratory
strains ATCC 27853 (at 3 × 104 CFU/mL) and PAO1 (at 3 × 100 CFU/mL) and clinical
isolates, CF1, CF2 (both at 3 × 103 CFU/mL), and CF3 (at 3 × 100 CFU/mL). A PBS control
and undisturbed larvae were included. Changes in hemocyte density were measured at 0,
2, 4, 6, 12, and 24 h post-inoculation by piercing the back of the anterior end of five larvae
(n = 3) with a sterile needle (25 gauge; BD Plastipak). Hemolymph was collected (50 µL)
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into a pre-chilled tube and diluted in cold PBS containing N-phenylthiourea (Sigma-Aldrich,
Kent, UK) to reduce clotting and prevent melanization [49]. Cell density was calculated
with a hemocytometer (Neubauer Tiefe) under the microscope.
2.4.3. Determination of G. mellonella Hemolymph Burden of P. aeruginosa
Groups of five larvae (n = 3) were infected with 20 µL of ATCC 27853 (3 × 104 CFU/mL),
PAO1 (3 × 100 CFU/mL) CF1 (3 × 103 CFU/mL), CF2 (3 × 103 CFU/mL), and CF3
(3 × 100 CFU/mL) into the last left pro-leg and incubated for 0, 2, 4, 6, 12, and 24 h. After
each time point, larval hemolymph (50 µL) was extracted and serially diluted in 450 µL of
0.9% NaCl in an iced tube. Each dilution was plated on Pseudomonas isolation agar (Lab M)
and colonies were counted after 24 h at 37 ◦ C. Data were expressed as viable CFU/mL.
2.5. Galleria mellonella Response to Metal-tdda-phen Complexes +/− Gentamicin
2.5.1. Toxicity Studies
The Cu-tdda-phen, Mn-tdda-phen, and Ag-tdda-phen complexes were first tested in
G. mellonella larvae to determine their levels of toxicity. Stock solutions of metal-tdda-phen
complexes and gentamicin were diluted in sterile water and the starting materials, phen and
tddaH2 , were diluted in methanol (10%). Twenty µL were inoculated into the G. mellonella
larvae through the last left pro-leg into the hemocoel using a Myjector U-100 insulin syringe
(Terumo Europe NV, Leuven, Belgium). Undisturbed larvae, larvae inoculated with water,
and larvae inoculated with methanol equivalent to the highest concentration present in
the dilutions (10%) acted as experimental controls. The larvae were placed in Petri dishes
containing wood shavings and incubated at 37 ◦ C for 96 h. Mortality, cuticle discoloration,
and response to touch were recorded every 12 h post-injection.
Once the toxicity profiles of each of the metal-tdda-phen complexes alone was established, they were individually assessed in combination with gentamicin. The working
solutions 500, 200, and 100 µg/mL of both the metal-tdda-phen complexes and gentamicin
were used in varying permutations by injection (20 µL) into the last left pro-leg. The larvae
were placed in Petri dishes containing wood shavings and incubated at 37 ◦ C and mortality,
cuticle discoloration, and response to touch were recorded every 12 h post-injection.
2.5.2. Determination of Hemocyte Density
Hemocyte densities were measured 2, 6, and 24 h post-inoculation with metal-tddaphen complexes alone (200 and 750 µg/mL) and in combination with gentamicin (200 and
750 µg/mL). A PBS control and undisturbed larvae were included. Changes in hemocyte
density were measured as previously described.
2.5.3. Gene Expression of Immune-Related Genes
RNA extraction and quantification, followed by cDNA synthesis, was first carried out
on G. mellonella larvae inoculated with the metal-tdda-phen complexes alone (750 µg/mL)
or in combination with gentamicin (100 µg/mL) prior to real-time PCR for the expression
of target immune-related genes. After 2, 6, and 24 h, five larvae (n = 3) were submerged
in liquid nitrogen and ground to a fine powder. One mL of TRI Reagent (Sigma-Aldrich,
Kent, UK) was added for the RNA extraction, and the mixture was transferred to a chilled
tube before centrifugation at 2000× g for 2 min. The supernatant was brought to a fresh
tube on ice and mixed with 200 µL of chloroform (ACS grade; Sigma-Aldrich, Kent, UK),
incubated for 3 min at room temperature, before centrifuging again at 4 ◦ C for 15 min at
12,000× g. The upper aqueous phase (200 µL) was carefully transferred into a tube, and
RNA was precipitated with isopropanol (500 µL) (ACS grade; Sigma-Aldrich, Kent, UK).
Tubes were then incubated at room temperature for 10 min and centrifuged at 4 ◦ C for
10 min at 12,000× g. The RNA pellet was washed once in 1 mL of 75% (v/v) ethanol (SigmaAldrich, Kent, UK), allowed to dry and re-suspended in nuclease-free water. The RNA
quantification was measured on a MultiskanTM GO (Thermo Scientific, Dublin, Ireland)
UV spectrophotometer with the µDrop plate.
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cDNA was then synthesized from the extracted RNA of each experimental condition
using the cDNA synthesis kit (Quanta BioSciences, Gaithersburg, MD, USA). Each reaction
was placed into the SimpliAmp Thermal Cycler (Applied Biosystems, Dublin, Ireland) for
5 min at 22 ◦ C, 30 min at 42 ◦ C, and 5 min at 85 ◦ C, followed by samples being held at 4 ◦ C
before the quantitative real-time PCR (qRT-PCR). Primer sets (forward and reverse primer
sequences detailed in Supplementary Table S1) [50] were obtained from Sigma-Aldrich and
SYBR Green I (KAPA SYBR FAST; Sigma-Aldrich, Kent, UK) was used as the reaction probe.
The samples were added to the 7500 Fast Real-Time PCR System (Applied Biosystems,
Dublin, Ireland). Thermal cycling was initiated with a pre-incubation at 95 ◦ C for 5 min,
followed by amplification for 45 cycles of 95 ◦ C for 10 s, 60 ◦ C for 10 s, and 72 ◦ C for 10 s,
melting curve at 95 ◦ C for 5 s, 65 ◦ C for 1 min, and 95 ◦ C for 10 s, and cooling at 40 ◦ C for
10 s. The assay was performed in triplicate. The relative gene expression was calculated
using the 2−∆∆Ct method, and the Ct values of all immune-related genes analyzed were
normalized against the expression of the reference gene (S7e).
2.6. Galleria mellonella Response to Pseudomonas aeruginosa Infection and Treatment with
Metal-tdda-phen Complexes +/− Gentamicin
2.6.1. Treatment of Metal-tdda-phen Complexes in G. mellonella Infected with P. aeruginosa
To ascertain the in vivo activity of metal-tdda-phen complexes alone, larvae were infected with each P. aeruginosa isolate (3 × 100 CFU/mL for PAO1 and CF3, 3 × 103 CFU/mL
for CF1 and CF2, and 3 × 104 CFU/mL for ATCC 27853) as described above and then
administered with either Cu-tdda-phen, Mn-tdda-phen, Ag-tdda-phen or gentamicin
(100–500 µg/mL) 1 h post-infection. Undisturbed larvae and larvae infected with the bacterial strains and PBS (untreated) were included as controls. All larvae were incubated at
37 ◦ C and assessed every 12 h for a total of 96 h for mortality and melanization.
2.6.2. Treatment of Metal-tdda-phen Complexes + Gentamicin in G. mellonella Infected with
P. aeruginosa
Similarly to the above, larvae were infected with bacterial strains (3 × 100 CFU/mL for
PAO1 and CF3, 3 × 103 CFU/mL for CF1 and CF2, and 3 × 104 CFU/mL for ATCC 27853)
and after 1 h post-inoculation, they were treated with a combination of metal-tdda-phen
complex (100 µg/mL) and gentamicin (100 µg/mL). All larvae were incubated at 37 ◦ C
and assessed every 12 h for a total of 96 h.
2.7. Statistical Analysis
All experiments were performed in three independent experimental sets and the
results are presented as the mean ± SE. All statistical analyses were performed with
GraphPad Prism 9.0 (GraphPad Software Inc., San Diego, CA, USA). Survival curves of
G. mellonella larvae experiments were generated using the Kaplan−Meier method and
differences in survival between groups were calculated using the log-rank (Mantel-Cox)
test, and Holm’s correction was applied for multiple comparisons. Two-way ANOVA was
used to compare the hemocyte densities and gene expression studies.
3. Results
3.1. Response of Galleria mellonella to Pseudomonas aeruginosa Infection
The effect of infection with P. aeruginosa laboratory strains ATCC 27853 and PAO1,
and clinical isolates CF1, CF2, and CF3, over a range of 3 × 100 to 3 × 105 CFU/mL, on
survival of G. mellonella larvae is presented in Figure 1. Larval survival was affected in an
inoculum-dependent manner during a 96 h incubation, with the greater CFU/mL injections
causing greater larval death. All infected larvae died at the highest tested concentration
(3 × 105 CFU/mL) within a 48 h period. In the set of uninfected and PBS injected larvae
used as a control, no death was observed. G. mellonella demonstrated the highest tolerance
towards laboratory strain ATCC 27853, an inoculum size of 3 × 104 CFU/mL induced
mortality rates of 46.7 ± 3.3% after 24 h and 60 ± 3.3%, 63.7 ± 5.7%, and 73.3 ± 3.3% over
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the following days, and 3 × 103 CFU/mL produced 26.7 ± 3.3% mortality after 24 h and
55 ± 5% by 96 h. Further dilutions (3 × 102 , 3 × 101 , 3 × 100 CFU/mL) produced less than
10% mortality over the entire examined time course. Injection with clinical isolates CF1
and CF2 incited similar pathogenicity profiles. At 3 × 104 CFU/mL, 53.3 ± 6.7% of larvae
died after 24 h with the injection of CF1, while 46.7 ± 3.3% mortality was observed after
infection with CF2. Over 90% death was recorded after 96 h of injection with either isolate.
A ten-fold reduction in inoculum resulted in similar mortality after 24 h (50 ± 3.3% with
CF1 and 56.7 ± 3.3% with CF2) with an 80 ± 5.7% mortality for both isolates by the end of
the experiment. Injection with lower dilutions (3 × 100 ; 3 × 101 ; 3 × 102 CFU/mL) resulted
in a 0–26.7 ± 3.3% mortality after 24 h and 0–56.7 ± 6.7% after 96 h. Laboratory strain
PAO1 and clinical isolate CF3 were the most virulent to the larvae, with a 20-µL inoculation
of 3 × 101 CFU/mL causing complete death after 24 h. This indicated the sensitivity of
G. mellonella to P. aeruginosa infection, which has previously been reported [51–53]. There
were significant differences (p < 0.05, p < 0.01, p < 0.001) between the virulence
Biomedicines 2022, 9, x FOR PEER REVIEW
7 of 24of the
examined strains and an inoculum that caused over 50% mortality within 48 h but not 100%
mortality within 24 h were chosen for subsequent studies.

Figure 1. Kaplan–Meier survival distributions for each P. aeruginosa strain (ATCC 27853, PAO1, CF1,
Figure 1. Kaplan–Meier survival distributions for each P. aeruginosa
strain (ATCC 27853, PAO1, CF1,
CF2, and CF3) assessed over varying inoculum doses (3 × 100 to 3 × 105 CFU/mL). Significance was
CF2, and CF3) assessed over varying inoculum doses (3 × 100 to 3 × 105 CFU/mL). Significance was
assessed
through
log-rank
(Mantel–Cox)
Holm’s
correction
was applied
for multiple
assessed
through
thethe
log‐rank
(Mantel–Cox)
test, test,
and and
Holm’s
correction
was applied
for multiple
comparisons
< 0.05,
p < 0.01,
p < 0.001).
comparisons
(*: (*:
p <p0.05,
**: p**:
< 0.01,
***: p***:
< 0.001).

3.2. Immune Response of Galleria mellonella to Pseudomonas aeruginosa Infection
Alterations in the number of circulating immune cells (hemocytes) within G.
mellonella have been used to indicate the larval immune response to a pathogen [54].
Drifting hemocytes are the initial responders to an infection, and their density can be
enhanced by the stimulation of those attached to the internal wall of the haemocoel or
bound to organs such as fat bodies [31]. Subsequent to the mortality studies, alterations in
hemocyte density following inoculation with P. aeruginosa strains ATCC 27583 (3 × 104
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3.2. Immune Response of Galleria mellonella to Pseudomonas aeruginosa Infection
Alterations in the number of circulating immune cells (hemocytes) within G. mellonella
have been used to indicate the larval immune response to a pathogen [54]. Drifting hemocytes are the initial responders to an infection, and their density can be enhanced by
the stimulation of those attached to the internal wall of the haemocoel or bound to organs such as fat bodies [31]. Subsequent to the mortality studies, alterations in hemocyte
density following inoculation with P. aeruginosa strains ATCC 27583 (3 × 1048 CFU/mL),
Biomedicines 2022, 9, x FOR PEER REVIEW
of 24
PAO1 (3 × 100 CFU/mL), CF1 (3 × 103 CFU/mL), CF2 (3 × 103 CFU/mL), and CF3
(3 × 100 CFU/mL) were assessed over a 24-h period (Figure 2A). All inoculated larvae
had increased levels of hemocytes relative to the initial injection (0 h). With strains PAO1
CF2 (13.62 ± 0.38 × 106/mL, p < 0.01), and ATCC 27853 (11.64 ± 0.51 × 106/mL). After 24 h of
and CF3, the inoculum saw a significant (p < 0.001 and p < 0.05, respectively) increase
monitoring, hemocytes populations had decreased but6remained elevated compared to
in hemocytes (12.98 ± 0.73 and 13.86 ± 1.09 × 10 /mL, respectively)
after 2 h. ATTC
their initial levels (0 h). Larvae infected with
PAO1 (7.59 ± 0.71 × 106/mL, p < 0.01), CF26
6 /mL
27853 had a count
of
9.69
±
0.62
×
10
at
2
h
while
CF1
had
10.93
±
1.31 × 10 /mL
(8.61 ± 0.55 × 106/mL, p < 0.05), and CF3
for 24 h (8.12 ± 1.06 × 106/mL, p < 0.05) showed a
and CF2 had 11.06 ± 1.00 × 106 /mL. Infections with all strains saw a spike in hemosignificant increase in hemocyte density compared to the controls, ATCC 27853 (8.81 ±
cyte populations after 4 h. The greatest response
was observed in larvae injected with
0.57 × 106/mL, p > 0.05) and
CF1 (8.51 ± 0.39 × 106/mL, p > 0.05) were not significant. 6
6
CF3The
(16.17
± 0.94process
× 10 /mL,
p < 0.001)
followed
by PAO1 (15.27
± 1.04 CFU
× 10 in/mL),
infection
was also
observed
by enumerating
P. aeruginosa
the CF1
6 /mL, p < 0.05), CF2 (13.62 ± 0.38 × 106 /mL, p < 0.01), and ATCC
(14.67
±
0.66
×
10
hemolymph of the infected6 larvae. Larvae were infected with ATCC 27853 (3 × 104
27853 (11.64
±(30.51
10 /mL).CF1
After
of monitoring,
populations
0 CFU/mL),
CFU/mL),
PAO1
× 10×
(3 ×24
103hCFU/mL),
CF2 (3 ×hemocytes
103 CFU/mL),
and CF3 had
decreased
but
remained
elevated
compared
to
their
initial
levels
(0
h).
Larvae
infected
0
(3 × 10 CFU/mL) and monitored over 24 h (Figure 2B). With initial time points (0 to 4 h),
6 /mL, p < 0.01), CF2 (8.61 ± 0.55 × 106 /mL, p < 0.05), and
with
PAO1
(7.59
±
0.71
×
10
a decrease in viable bacterial cells was observed. Bacterial burden in larvae infected with
for 24strains
h (8.12increased
± 1.06 ×from
106 /mL,
showed
a significant
increase
hemocyte
allCF3
bacterial
4 andp24< h0.05)
analysis
points,
strains ATCC
27853,in
PAO1,
6 /mL, p > 0.05) and CF1
density
compared
to
the
controls,
ATCC
27853
(8.81
±
0.57
×
10
CF1, and CF2 increased to a median value >5 log10 CFU/mL while CF3 increased to a
6
(8.51 ±value
0.39 ×
p > 0.05) were not significant.
median
>4 10
log/mL,
10 CFU/mL.

Figure
G.mellonella
mellonellawith
with
aeruginosa
strains
ATCC
(3 4×CFU/mL),
104
Figure2.2.Following
Followingthe
theinoculation
inoculation of G.
P. P.
aeruginosa
strains
ATCC
2758327583
(3 × 10
0 CFU/mL), CF1 (3 × 103 CFU/mL),
3 CFU/mL),
0
0
3
3
CFU/mL),
PAO1
(3
×
10
CF2
(3
×
10
and
CF3
(3
×
10
PAO1 (3 × 10 CFU/mL), CF1 (3 × 10 CFU/mL), CF2 (3 × 10 CFU/mL), and CF3
CFU/mL),0 the (A) alteration in circulating hemocyte density and (B) bacterial burden, was assessed
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3.3. Galleria mellonella Response to Metal‐tdda‐phen Complexes
The infection process was also observed by enumerating P. aeruginosa CFU in the
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melanization was observed. Gandra et al. [39] investigated the toxicity of one copper(II)‐
phen, seven manganese(II)‐phen, and three silver(I)‐phen‐complexes towards G.
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larvae exposed to the solvent control did demonstrate slight to moderate melanization as
presented in Figure 3. All larvae tolerated 2–10 µg/larvae (1.6–13.59 µM) of the metal-tddaphen complex with no mortality observed over the entire experiment. Similarly, complexes
Mn-tdda-phen and Ag-tdda-phen induced no mortality at 15 µg/larvae (20.39 and 12.5 µM,
respectively) while doubling the concentration (40.78 and 24.9 µM, respectively) resulted in
6.66 ± 5.77% death for the former and 23.33 ± 5.77% death for the latter, after exposure
for 72 h. Cu-tdda-phen was the most toxic to the larvae, a concentration of 15 µg/larvae
(20.15 µM) resulted in a mortality rate of 53.33 ± 5.77% after 72 h and increasing the
dose to 30 µg/larvae (40.3 µM) saw complete death of all tested larvae after the same
amount of time. It is well known that copper is highly toxic to mammals, and similar
studies investigating Cu-phen complexes and their derivatives have also highlighted their
lethality towards G. mellonella [28,35]. Although lower concentrations of Cu-tdda-phen did
not induce mortality, moderate to severe melanization was observed. Gandra et al. [39]
investigated the toxicity of one copper(II)-phen, seven manganese(II)-phen, and three
silver(I)-phen-complexes towards G. mellonella, and of this panel Mn-tdda-phen (chelate 8),
Cu-tdda-phen (chelate 1), and Ag-tdda-phen (chelate 10) were included. The group also
reported the low mortality rate induced in larvae by Mn-tdda-phen (13.33 ± 5.77%) and
Ag-tdda-phen (33.33 ± 5.77%) at high concentrations (30 µg/larvae) and the toxicity of
Cu-tdda-phen (100% mortality), corroborating the results obtained in this study.
Table 1. Mean larval mortality (%) after 24, 48, and 72 h inoculations with metal-tdda-phen complexes
and gentamicin at a concentration range of 2–30 µg/larvae.
Mean Mortality (%) +/− SE over Time (h)

Test Complex

Dose µg/Larvae
(µM)

24 h

48 h

72 h

Mn-tdda-phen

2 µg (2.71 µM)
4 µg (5.42 µM)
10 µg (13.59 µM)
15 µg (20.39 µM)
30 µg (40.78 µM)

0±0
0±0
0±0
0±0
0±0

0±0
0±0
0±0
0±0
6.66 ± 5.77

0±0
0±0
0±0
0±0
6.66 ± 5.77

Cu-tdda-phen

2 µg (2.68 µM)
4 µg (5.36 µM)
10 µg (13.41 µM)
15 µg (20.15 µM)
30 µg (40.3 µM)

0±0
0±0
0±0
23.33 ± 5.77
76.66 ± 5.77

0±0
0±0
0±0
46.66 ± 5.77
83.33 ± 5.77

0±0
0±0
0±0
53.33 ± 5.77
100 ± 0

Ag-tdda-phen

2 µg (1.6 µM)
4 µg (3.3 µM)
10 µg (8.3 µM)
15 µg (12.5 µM)
30 µg (24.9 µM)

0±0
0±0
0±0
0±0
3.33 ± 5.77

0±0
0±0
0±0
0±0
23.33 ± 5.77

0±0
0±0
0±0
0±0
23.33 ± 5.77

Gentamicin

2 µg (3.5 µM)
4 µg (6.9 µM)
10 µg (17.4 µM)
15 µg (26.1 µM)
30 µg (52.1 µM)

0±0
0±0
0±0
0±0
0±0

0±0
0±0
0±0
0±0
13.33 ± 5.77

0±0
0±0
0±0
0±0
13.33 ± 5.77

Phen

2 µg (11.1µM)
4 µg (22.2 µM)
10 µg (55.5 µM)
15 µg (83.2 µM)
30 µg (166.5 µM)

0±0
0±0
53.3 ± 5.8
76.7 ± 5.8
100 ± 0

0±0
0±0
53.3 ± 5.8
76.7 ± 5.8
100 ± 0

0±0
0±0
53.3 ± 5.8
76.7 ± 5.8
100 ± 0

tddaH2

2 µg (9 µM)
4 µg (18 µM)
10 µg (45 µM)
15 µg (67.5 µM)
30 µg (135 µM)

0±0
0±0
0±0
0±0
46.7 ± 5.8

0±0
0±0
0±0
0±0
46.7 ± 5.8

0±0
0±0
0±0
0±0
46.7 ± 5.8

Data are presented as mean ± SE.

tddaH2
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2 μg (9 μM)
4 μg (18 μM)
10 μg (45 μM)
15 μg (67.5 μM)
30 μg (135 μM)

0±0
0±0
0±0
0±0
46.7 ± 5.8

0±0
0±0
0±0
0±0
46.7 ± 5.8

0±0
0±0
0±0
0±0
46.7 ± 5.8
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Data are presented as mean ± SE.

Figure 3. G. mellonella representing the different levels of melanization and cuticle discoloration.

Injection of the control antibiotic, gentamicin at 30 µg/larvae (52.1 µM) induced
13.33 ± 5.77% mortality after 48 h. Surviving larvae presented with slight to moderate
melanization and some were slow to respond to stimulation. In addition, the larvae were
injected with the metal-tdda-phen complexes starting materials, 3,6,9-trioxaundecanedioic
acid (tddaH2 ) and 1,10-phenanthroline (phen) to ensure the recorded effects were not a result of the free ligands alone but the complex itself. The highest dose (30 µg/larvae, 135 µM)
of tddaH2 saw 46.7 ± 5.8% of the inoculated larvae perish while 10 µg/larvae (45 µM) resulted in a mortality of 53.3 ± 5.8% after the initial 24 h. Kellett et al. [55] also demonstrated
that G. mellonella exposed to high concentrations of phen (5000 and 2000 µg mL−1 ) had poor
tolerance (100% and 90% mortality, respectively). Interestingly, the G. mellonella larvae that
were exposed to lower doses of phen (2–4 µg/larvae, 11.1–2.2 µM), although they survived,
showed an orange discoloration of the cuticle post-injection (Figure 3). It was postulated
that the orange discoloration was a result of the phen interfering with the copper containing
enzyme phenoloxidase that drives melanin synthesis [43]. To identify whether metal-tddaphen complexes induced an immunomodulatory effect, larval hemocytes were withdrawn
and counted after exposure to a low (2 µg/larvae) and high (15 µg/larvae) dose that did
not induce 100% mortality. At 2 h, both low and high doses prompted similar responses
in subjected larvae: Ag-tdda-phen (11.20 ± 0.47 × 106 /mL and 12.44 ± 0.54 × 106 /mL,
respectively), Mn-tdda-phen (7.95 ± 0.37 × 106 /mL and 11.43 ± 0.56 × 106 /mL, respectively), phen (10.8 ± 0.46 × 106 /mL and 8.8 ± 0.24 × 106 /mL, respectively), and tddaH2
(7.78 ± 0.34 × 106 /mL and 8.30 ± 0.55 × 106 /mL, respectively) showed a significant
(p < 0.05) increase compared to the control (Figure 4). After an extended exposure to
15 µg/larvae to 6 h, Mn-tdda-phen (42.34 ± 0.95 × 106 /mL) and Ag-tdda-phen
(32.71 ± 0.75 × 106 /mL) significantly enhanced hemocyte density that continued to the
24 h time point (135.82 ± 4.29 and 133.14 ± 2.59 × 106 /mL, respectively). This demonstrates
that at higher concentrations, these metal-tdda-phen complexes induce a priming effect
within the insects. There were no hemocytes when phen was assessed at 15 µg/larvae after
24 h, and reduced hemocytes when Cu-tdda-phen (20.66 ± 0.61 × 106 /mL) was examined
at the same concentration. The toxicity of these compounds to larvae at this concentration
could be responsible for this response.
Larvae treated with Mn-tdda-phen, Cu-tdda-phen, Ag-tdda-phen, and gentamicin
(15 µg/larvae) were incubated for 2, 6, and 24 h prior to assessment of immune related
gene expression. Transferrin (iron-binding protein), IMPI (inducible metallo-proteinase
inhibitor), galiomicin (defensin), and gallerimycin (cysteine-rich antifungal peptide) genes
were normalized against the expression of S7e (reference gene) and larval treatments
were compared to the PBS injected control and are presented in Figure 5. Expression
of transferrin and IMPI encoding genes were significantly (p < 0.05) upregulated by Mntdda-phen and Ag-tdda-phen across all time points. A time-dependent induction of both
genes was observed reaching the maximum 24 h after injection. This suggests that these
metal-tdda-phen complexes are initiating an immune response in the larvae.
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Larvae treated with Mn‐tdda‐phen, Cu‐tdda‐phen, Ag‐tdda‐phen, and gentamicin
(15 μg/larvae) were incubated for 2, 6, and 24 h prior to assessment of immune related
gene expression. Transferrin (iron‐binding protein), IMPI (inducible metallo‐proteinase
inhibitor), galiomicin (defensin), and gallerimycin (cysteine‐rich antifungal peptide) genes
were normalized against the expression of S7e (reference gene) and larval treatments were
compared to the PBS injected control and are presented in Figure 5. Expression of
transferrin and IMPI encoding genes were significantly (p < 0.05) upregulated by Mn‐tdda‐
phen and Ag‐tdda‐phen across all time points. A time‐dependent induction of both genes
was observed reaching the maximum 24 h after injection. This suggests that these metal‐
tdda‐phen complexes are initiating an immune response in the larvae.

Figure 5. Relative expression of genes involved in the immune response of G. mellonella when exposed
Figure 5. Relative expression of genes involved in the immune response of G. mellonella when
to metal-tdda-phen complexes, gentamicin and phen after 2, 6, and 24 h post-injection. * indicate
exposed to metal‐tdda‐phen complexes, gentamicin and phen after 2, 6, and 24 h post‐injection. *
significant
differences
to the PBS
injected
control (p
< 0.05).
indicate
significant
differences
to the
PBS injected
control
(p < 0.05).

3.4. Galleria mellonella Response to Metal‐tdda‐phen Complexes and Gentamicin
After toxicity studies of the metal‐tdda‐phen complexes and gentamicin as single
agents, the dual administration of the complexes and antibiotic were assessed within the
larval model. The lowest examined concentrations that did not induce mortality (Table 1)
were examined in varying permutations of 2–10 μg/larvae and observed over three time
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3.4. Galleria mellonella Response to Metal-tdda-phen Complexes and Gentamicin
After toxicity studies of the metal-tdda-phen complexes and gentamicin as single
agents, the dual administration of the complexes and antibiotic were assessed within
the larval model. The lowest examined concentrations that did not induce mortality
(Table 1) were examined in varying permutations of 2–10 µg/larvae and observed over
three time points (24, 48, and 72 h) (Table 2). Overall, the combination of agents, even
at lower doses, enhanced toxicity towards the larvae when compared to their toxicity
as singular drugs. The highest dose of gentamicin (10 µg/17.4 µM) with Mn-tdda-phen
(10 µg/13.59 µM), Cu-tdda-phen (10 µg/13.41 µM), and Ag-tdda-phen (10 µg/8.3 µM)
resulted in 86.7, 100, and 93.3% mortality, respectively, after 72 h. While the highest dose of
gentamicin (10 µg/17.4 µM) with the lowest dose of Mn-tdda-phen (2 µg/2.71 µM) and
Ag-tdda-phen (2 µg/1.6 µM) produced mortality rates of 46.7 and 53.3%, respectively,
the combination with Cu-tdda-phen (2 µg/2.68 µM) incited 83% mortality. The lowest
concentration of gentamicin (2 µg/2.35 µM) with both Mn-tdda-phen (2 µg/2.71 µM) and
Ag-tdda-phen (2 µg/1.6 µM) induced complete survival of all injected larvae and with
Cu-tdda-phen (2 µg/3.5 µM), 26.7% mortality was noted. A high and low and a low and
high dose of gentamicin with both Mn-tdda-phen and Ag-tdda-phen exerted a similar
toxicity profile in larvae (43.3–53.3% mortality) suggesting that a combination of agents
overstimulate the animal, irrespective of the higher concentration. In contrast, a higher dose
of Cu-tdda-phen (10 µg/13.41 µM) with a lower dose of gentamicin (2 µg/2.35 µM) induced
an elevated mortality (83.3%) than the reverse (73.3%), suggesting that Cu-tdda-phen is
driving the toxicity towards G. mellonella.
Table 2. Mean larval mortality (%) after 24, 48, and 72 h inoculation of Mn-tdda-phen and gentamicin,
Cu-tdda-phen and gentamicin, and Ag-tdda-phen and gentamicin.

Test Agents

Dose µg/Larvae (µM)

Mean Mortality (%) +/− SE over Time (h)
24 h

48 h

72 h

Mn-tdda-phen +
Gentamicin

2 µg (2.71 µM) + 2µg (3.5 µM)
4 µg (5.42 µM) + 4 µg (6.9 µM)
10 µg (13.59 µM) + 10 µg (17.4 µM)
2 µg (2.71 µM) + 10 µg (17.4 µM)
10 µg (13.59 µM) + 2 µg (3.5 µM)

0±0
20 ± 5.8
83.3 ± 3.3
43.3 ± 3.3
46.7 ± 3.3

0±0
20 ± 5.8
86.7 ± 3.3
46.7 ± 3.3
50.0 ± 5.8

0±0
20 ± 5.8
86.7 ± 3.3
46.7 ± 3.3
53.3 ± 3.3

Cu-tdda-phen +
Gentamicin

2 µg (2.68 µM) + 2µg (3.5 µM)
4 µg (5.36 µM) + 4 µg (6.9 µM)
10 µg (13.41 µM) + 10 µg (17.4 µM)
2 µg (2.68 µM) + 10 µg (17.4 µM)
10 µg (13.41 µM) + 2 µg (3.5 µM)

26.7 ± 3.3
70 ± 5.8
100 ± 0
63.3 ± 3.3
83.3 ± 3.3

26.7 ± 3.3
73.3 ± 3.3
100 ± 0
66.7 ± 3.3
83.3 ± 3.3

26.7 ± 3.3
73.3 ± 3.3
100 ± 0
73.3 ± 3.3
83.3 ± 3.3

Ag-tdda-phen +
Gentamicin

2 µg (1.6 µM) + 2µg (2.5 µM)
4 µg (3.3 µM) + 4 µg (6.9 µM)
10 µg (8.3 µM) + 10 µg (17.4 µM)
2 µg (1.6 µM) + 10 µg (17.4 µM)
10 µg (8.3 µM) + 2 µg (2.5 µM)

0±0
26.7 ± 3.3
83.3 ± 3.3
43.3 ± 3.3
46.7 ± 6.7

0±0
33.3 ± 3.3
93.3 ± 6.7
53.3 ± 3.3
50 ± 5.8

0±0
33.3 ± 5.8
93.3 ± 6.7
53.3 ± 3.3
53.3 ± 3.3

Data are presented as mean ± SE.

To further investigate the combined effect of metal-tdda-phen complexes and gentamicin on the immune system of the larvae, hemocytes were extracted and enumerated
(Figure 6). The combination of Mn-tdda-phen (2 (2.71 µM)—4 µg (5.42 µM)) with gentamicin (2 (3.5 µM)—4 µg (6.9 µM)) elicited the greatest hemocyte response at 2 (7.59 ± 0.38
and 9.82 ± 0.74 × 106 /mL, respectively), 6 (20.44 ± 0.61 and 34.67 ± 1.64 × 106 /mL, respectively), and 24 h (90.61 ± 2.56 and 93.48 ± 2.04 × 106 /mL, respectively). Administration of
Cu-tdda-phen with gentamicin to larvae produced similar hemocyte densities at both low
(2 (2.71 µM) + 2µg (3.5 µM)) and high doses (4 (5.36 µM) + 4 µg (6.9 µM)) at 2 (6.48 ± 0.57
and 8.14 ± 1.24 × 106 /mL, respectively) and 6 h (15.44 ± 0.56 and 18.21 ± 0.52 × 106 /mL,
respectively). After 24 h, a hemocyte count of Cu-tdda-phen and gentamicin could not be
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determined due to the high mortality rate. Unlike the other combinations, Ag-tdda-phen
and gentamicin induced a more pronounced hemocyte response at lower concentrations
Biomedicines Biomedicines
2022, 9, x FOR
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14 of 24 14 of 24
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than higher after 2 (11.20 ± 0.47 and 10.29 ± 0.59 × 106 /mL, respectively) and 24 h
(75.28 ± 2.28 and 47.92 ± 2.88 × 106 /mL, respectively).
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Figure 7. Relative expression of genes involved in the immune response of G. mellonella when exposed
to metal-tdda-phen complexes in combination with gentamicin (CN) after 2, 6, and 24 h post-injection.
* indicate significant differences to the PBS control (p < 0.05).
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3.5. Effect of Metal-tdda-phen Complexes in Treating Pseudomonas aeruginosa Infection in Galleria
mellonella +/− Gentamicin
After screening the bacterial strains in the larval model, an infective dose was determined for each strain. Larvae were inoculated with ATCC 27583 (3 × 104 CFU/mL),
PAO1 (3 × 100 CFU/mL), CF1 (3 × 103 CFU/mL), CF2 (3 × 103 CFU/mL), and CF3
(3 × 100 CFU/mL), and subsequently received a single dose of the metal-tdda-phen complexes alone (2–10 µg/larvae) (1.6–13.59 µM), gentamicin (2–10 µg/larvae) (3.5–17.4 µM)
alone, or the metal-tdda-phen complex (1 µg/larvae) (831.3 nM–1.36 µM) in combination
with gentamicin (1 µg/larvae) (1.74 µM) 1 h post-infection.
The effect of single doses of metal-tdda-phen complexes or gentamicin on survival of
G. mellonella inoculated with P. aeruginosa strains, ATCC 27853 (A-D), PAO1 (E-H), CF1 (I-L),
CF2 (M-P), CF3 (R-U), are presented in Figure 8. Overall, the exposure to a metal-tdda-phen
complex increased survival in infected larvae. Gentamicin (10 µg/larvae) (17.4 µM) was
the most effective at treating larvae infected with ATCC 27853 which had no mortalities
after 96 h when compared to the PBS control (73.33 ± 3.3% mortality). All metal-tdda-phen
complexes decreased mortality (26.7–36.7%) at the same concentration and time point.
When larvae were inoculated with PAO1, a more virulent strain, mortality increased, except
for Cu-tdda-phen treatment. G. mellonella presented with a metal-tdda-phen complex or
gentamicin increased survival in a dose-dependent manner. Larvae administered 10 µg of
gentamicin (17.4 µM) had a 23.3 ± 3.3% mortality rate. Those exposed to Mn-tdda-phen
(13.59 µM) and Ag-tdda-phen (8.3 µM) at 10 µg/larvae prolonged survival of PAO1 infected
larvae. At 48 h, the mortality rate was 26.7 ± 3.3% of larvae presented with Mn-tdda-phen
and 40 ± 5.8% of larvae subjected to Ag-tdda-phen, compared to 66.7 ± 6.7% of larvae that
received PBS. G. mellonella that encountered 10 µg (13.41 µM) of Cu-tdda-phen showed a
higher mortality rate (70 ± 0%) at 48 h than those that were given PBS. Due to the toxicity
of this complex in larvae, the stress of both seemed to elevate mortality. However, a lower
dose of 4 µg/larvae produced a mortality rate of 36.7 ± 3.7 at 48 h. This was expected
as Mn-tdda-phen and Ag-tdda-phen presented with lower toxicity towards G. mellonella
(Table 2) and induced the immune response (Figure 6) of the larvae, compared to their
copper equivalent. We have previously reported the susceptibility profiles of laboratory
strains and clinical isolates CF1-CF3 to gentamicin [27] in vitro. ATCC 27853 and PAO1
were susceptible to gentamicin with MICs of 1 (1.7 µM) and 2 µg/mL (3.5 µM), respectively,
while all the clinical isolates (MICs of 8 (13.9 µM) to over 256 µg/mL (445 µM)) were
deemed resistant to the antibiotic. Similarly in the G. mellonella model, the antibiotic efficacy
against the clinical isolates decreased compared to the laboratory strains. Larvae infected
with CF1, CF2, and CF3 and subsequently treated with the highest dose of gentamicin
(10 µg/larvae) (17.4 µM) saw survival recorded at 30 ± 0%, 70 ± 5.8%, and 76.7 ± 3.3%,
respectively, after 96 h. At the lowest investigated concentrations of metal-tdda-phen
complexes (2 µg/larvae) (1.6–2.71 µM), mortality rates were noted at 33.3–43.3% for CF1
and CF2. This activity was not maintained with CF3 however, treatment of metal-tddaphen complexes extended survival when compared to the PBS treated larvae. After 48 h,
larvae treated with Mn-tdda-phen (5.42 µM), Cu-tdda-phen (5.36 µM), and Ag-tdda-phen
(3.3 µM) at 4 µg/larvae had mortality rates of 50 ± 0%, 60 ± 5.8%, and 53.3 ± 3.3%,
respectively, compared to a 66.7 ± 3.3% of larvae that received PBS. Again, this activity
profile draws similarities to the result obtained when assessed in vitro; metal-tdda-phen
complexes were the most active against CF1 and CF2 (with MICs of 8–16 µg/mL); however,
a higher concentration was needed to inhibit CF3 (MICs of 64–128 µg/mL).
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In an effort to improve therapeutic outcome, many clinicians recommend dual combinations of antibiotics to increase the likelihood of achieving appropriate therapy of
multidrug-resistant P. aeruginosa infections [56]. We also demonstrated synergistic activity against P. aeruginosa between all three complexes and gentamicin in vitro [27]. The
efficacy of metal-tdda-phen complexes in combination with gentamicin was measured in
G. mellonella larvae infected with ATCC 27583 (3 × 104 CFU/mL), PAO1 (3 × 100 CFU/mL),
CF1 (3 × 103 CFU/mL), CF2 (3 × 103 CFU/mL), and CF3 (3 × 100 CFU/mL). A single dose
of both Mn-tdda-phen (1.36 µM) and gentamicin (1.74 µM), Cu-tdda-phen (1.34 µM) and
gentamicin, and Ag-tdda-phen (868.5 nM) and gentamicin at 1 µg/larvae was administered
1 h post-infection and monitored for 96 h (Figure 9). This concentration was chosen as no
mortality was observed when dual administered to larvae (data not shown). Overall, a
combination of both drugs outperformed either as a single entity. Of the combinations,
larvae that received Mn-tdda-phen and gentamicin and Ag-tdda-phen and gentamicin, had
the lowest mortality across all strains. Both combinations decreased mortality by 50–53.3%,
Biomedicines 2022, 9, x FOR PEER REVIEW
17 of 24
compared to the PBS treated larvae, while Cu-tdda-phen and gentamicin decreased mortality by 43.3–50%.
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4. Discussion
Pseudomonas aeruginosa is a versatile opportunistic pathogen that causes severe
clinical complications due to its large genome that harbours an extensive arsenal of
virulence factors and antibiotic resistance determinants [57]. The bacterium is well
reported to swiftly adapt to conditions in the airway with exceptional metabolic flexibility
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To complement the survival data, the effect of these combinations was also assessed
through analyzing larval bacterial burden of P. aeruginosa compared to the effect of their
constituent mono-therapies and PBS treated larvae (Figure 9). Analysis after 24 h demonstrated that all combinations significantly reduced the bacterial population in the infected
larvae. G. mellonella infected with ATCC 27853 or PAO1 and subsequently treated with
metal-tdda-phen complexes in combination with gentamicin had a 6–7 log10 CFU/mL
reduction in comparison to PBS treated larvae. Activity was maintained across clinical
isolates, CF1–CF3, which had 4–6 log10 CFU/mL in circulating cells that were exposed to
both metal-tdda-phen complexes and gentamicin.
4. Discussion
Pseudomonas aeruginosa is a versatile opportunistic pathogen that causes severe clinical
complications due to its large genome that harbours an extensive arsenal of virulence
factors and antibiotic resistance determinants [57]. The bacterium is well reported to swiftly
adapt to conditions in the airway with exceptional metabolic flexibility and ability to evade
host immune attack [58]. The presence of P. aeruginosa is a particular threat for cystic fibrosis
(CF) patients. The deleterious impact that chronic infection has on lung function in CF has
been well described and often indicates poor clinical outcomes. P. aeruginosa infections are
becoming more challenging to treat due to the inherent resistance to many antibiotics, and
the prevalence of multidrug-resistance is increasing worldwide [59]. Moreover, persistent
P. aeruginosa infections in CF patients is due to the bacteria’s affinity to biofilm formation
which are exceedingly more resistant to treatment than their planktonic form [60,61]. Thus,
our previous report on the metal-tdda-phen complex capabilities against established mature
biofilms and synergistic activity with gentamicin warranted the in vivo studies to further
explore the hypothesis that these complexes could be potential therapeutics for treating
P. aeruginosa infection as a mono- or combination-therapy.
The use of Galleria mellonella larvae as a model to study pathogenicity and virulence,
the toxicity of novel complexes, and their efficacy as therapies is now well established. Entomopathogenic strains, such as ATCC 27853 and PAO1, and clinical isolates of P. aeruginosa,
are highly virulent in G. mellonella with lethal doses ranging from 2 to 100 CFU, killing
infected larvae within 24–48 h [40,51,62–64]. Similar pathogenicity profiles were observed
in this study. For instance, PAO1 and CF3 resulted in complete larvae death after 24 h at
30 CFU. Mortality assays demonstrated that the metal-tdda-phen complexes are well tolerated by G. mellonella up to 10 µg per exposed larvae. At the highest examined concentration
(30 µg/larvae), Cu-tdda-phen was extremely toxic to the larvae while Mn-tdda-phen was
the least toxic. This was also previously reported within our research group [39] demonstrating the reproducibility of this model. G. mellonella have been employed to evaluate
the toxicity of a range of agents and the results have shown a strong correlation to those
generated utilizing mammalian models. Maguire et al. reported comparable toxicology
data (LD50 ) of food preservatives between insect larvae and rats; consequently, Mn-tddaphen and Ag-tdda-phen complexes could be well tolerated by a mammalian model [65].
Furthermore, Mn-tdda-phen demonstrated immunomodulation properties by simulating
hemocyte density and immune-related genes, specifically antimicrobial peptides (AMPs)
transferrin (iron-binding protein) and IMPI (inducible metallo-proteinase inhibitor). AMPs
have been reported to exert their antimicrobial action through permeabilizing the pathogen
membrane and thus their upregulation may aid in the clearing of an infection.
Rapidly increasing antibiotic resistance in already difficult to treat pathogens have
prompted a variety of studies employing G. mellonella larvae to delineate the efficacy of
therapies against these problematic bacteria [66–68]. Within these studies, the antibiotic
susceptibility profiles of the examined microorganisms are mirroring those established
in vitro. Moreover, it has been shown that the MICs of anti-pseudomonal drugs in infected
larvae correlated with the susceptibilities in patients [38,52]. We have previously reported
the antibacterial capabilities of Mn-tdda-phen, Cu-tdda-phen, and Ag-tdda-phen against
P. aeruginosa strains originating from CF patients in vitro. While gentamicin was the most
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effective compound against the reference antibiotic-sensitive strains (ATCC 27853 and
PAO1), it had reduced efficacy across the resistant clinical isolates (CF1–CF3). However, the
metal-tdda-phen complexes maintained activity that was clinically relevant. Similarities can
been seen in the treatment of infected G. mellonella larvae. Gentamicin (at the highest tested
concentration of 10 µg/larvae) had the greatest potency in treating larvae infected with
ATCC 27853 and PAO1 but its activity decreased when administered to larvae infected with
the clinical isolates, which had been classified as resistant to the antibiotic [27]. However,
and mirroring the in vitro profiles, the activity of gentamicin diminished across the clinical
isolates while the activity of the metal-tdda-phen complexes was preserved.
Although definitive treatment with a single agent would be the ideal scenario, due to
the expanding resistance profiles of P. aeruginosa the empirical administration of antibiotic
combinations is utilized by clinicians to control pulmonary exacerbations in CF patients.
Across published guidelines, the most common combinations are an aminoglycoside or a
fluoroquinolone with an anti-pseudomonal β-lactam, which results in a synergistic bactericidal effect [69]. Gentamicin is a clinically important aminoglycoside antibiotic. It inhibits
protein synthesis by binding with a high affinity to the aminoacyl-tRNA site (A site) within
the 30S ribosomal subunit, thereby inhibiting the translation process [70]. This produces
truncated proteins, affecting the cell wall composition, which increases membrane permeability and subsequently heightens uptake of the drug [71]. However prolonged treatment
with gentamicin can have severe adverse effects, such as nephrotoxicity and ototoxicity that
are thought to be dose related, with higher concentrations causing greater chance of toxicity.
Metal-based drugs have unique mechanisms of action, in comparison to their organic
counterparts [14,15,72–77]. Such mechanisms include; ligand exchange or release, ROS generation and catalytic generation of toxic species or depletion of essential substrates [72,73].
These mechanisms can be multimodal [75] in nature and are hugely dependent on the
metal center and attached ligands [73]. In this study, we assessed the combination of the
metal-tdda-phen complexes and gentamicin because they demonstrated synergistic activity
against P. aeruginosa strains in both planktonic (data not shown) and biofilm forms [27]. The
combined therapy of metal-tdda-phen and gentamicin in larvae infected with all strains
produced an appreciable increase in survival than those treated with the individual agents,
at lower concentrations. Furthermore, combination dampened proliferation of bacteria
within the larvae which was elucidated by the larger depletion in bacterial burden in
comparison to single treatments. As bacteria adapt to antibiotic treatment, higher doses
are required to manage the infection which, as previously mentioned, has been associated
with severe adverse effects in patients. The efficacy of the metal-tdda-phen/gentamicin
combination at clearing an infection, especially of the resistant clinical isolates, at lower
doses is interesting in this regard. Although gentamicin is a bactericidal antibiotic, it is
not possible to deduce if the combination is also working in this manner. However, due to
the already established antibacterial effects of complex Mn-tdda-phen and its presented
capability to induce an immune response through enhancement of hemocytes and immune
related genes, it can be postulated that this complex might have several processes for aiding
the clearance of an infection.
5. Conclusions
In conclusion, the data presented here suggest that Mn-tdda-phen and Ag-tddaphen are capable of clearing a P. aeruginosa infection at concentrations that are non-toxic
towards G. mellonella larvae. Building on previously published work, the metal-tdda-phen
complexes are thought to be multimodal, acting directly on the bacteria but also through
stimulating both the cellular and humoral responses that work concomitantly to clear an
infection. Although more research is required to understand the mechanisms by which the
complexes exert their antibacterial properties, this study highlighted that substituting the
metal center alters the toxicity level and immunomodulation properties. Combinations of
metal-tdda-phen complexes with gentamicin were able to restore activity of the antibiotic
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against clinical isolates that were resistant to it, presenting an alternative combination
therapeutic approach with greater efficacy.
Supplementary Materials: The following supporting information can be downloaded at: https://
www.mdpi.com/article/10.3390/biomedicines10020222/s1, Table S1. Forward and reverse primers
for genes related to the immune response of G. mellonella.
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